http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2644947-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb972790dff0b1a791b74fbaacc1a424 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 |
| filingDate | 2013-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08270546f57738e1c8db4ee837025f22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b54ad711f285c29fc8e42bf59167cc2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96f91e41d2a757e0d8ffab1117ea3059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9692373e0839abe9ab7f0ffd83acfba7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc16cb6bddc6d40f0b06ec696f1f8c40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_161e5d2444b112250c1e18134e0723dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f2e9776e3c7b46a90c712ad90350b4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a818247270d3a6d4501530f9d6e3fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8923ef33d9287edfa61af897e5350f94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9d4021028dbca3731c7e695d891e819 |
| publicationDate | 2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2644947-C2 |
| titleOfInvention | Serin / treonin kinase inhibitors for treating of hyperopliferative diseases |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to the field of organic chemistry, namely a heterocyclic compound of formula (I) or a stereo-isomer thereof or a pharmaceutically acceptable salt, where X is CH or N; Z is (i) NH(CH 2 ) n CHR 1 Ar, where n is 0 or 1, or (ii) is 1-alkyl-4-aryl-pyrrolidin-3-ylamine, where alkyl is C 1 alkyl, optionally substituted with a phenyl ring, and aryl is methoxy substituted phenyl; R 1 is (a) hydrogen, (b) C 1 -C 6 alkyl optionally substituted with a hydroxyl group, (c) from 4 to 5 member heterocycle containing 1 hetero atom selected from N, where the heterocycle is optionally substituted with one group selected from the group consisting of halogen, or (d) 5 member heteroaryl containing 1 or 2 hetero atoms selected from N, where heteroaryl is optionally substituted with one group selected from C 1-6 alkyl; Ar is phenyl, pyridinyl or indolyl optionally substituted with from 1 to 2 groups independently selected from (a) C 1-6 alkoxy, (b) halogen, (c) C 1-6 halogenalkoxy, (d) cyano, (e) benzyl, (f) phenoxy, where said phenoxy is optionally substituted with halogen or C 1-6 alkyl, (g) 4-methylpiperazin-1-yl or (h) heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl and pyrazolyl, where said heteroaryl is optionally substituted with one C 1-10 alkyl; R 2 is selected from the group consisting of (a) C 1-5 hydroxyalkyl, (b) C 1-6 haloalkyl, (c) heterocyclyl, where said heterocyclyl is selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, 2-oxa-bicyclo[2,2,1]heptan-5-yl and pyrrolidinyl, and where said heterocyclyl is optionally substituted with 1 group independently selected from the group consisting of halogen, C 1-3 hydroxyalkyl or oxo, (d) heteroaryl, where said heteroaryl is selected from the group consisting of pyrazolyl and pyridinyl, and where said heteroaryl is optionally substituted with 1-2 C 1-3 alkyl groups, (e) C 3 cycloalkyl-C 1-2 alkyl, where said C 3 cycloalkyl-C 1-2 alkyl is optionally substituted with hydroxyl. Invention is also relates to a pharmaceutical composition based on a compound of formula (I), method of ERK protein kinase activity inhibiting, method of a hyperproliferative disorder treating or severity reducing and the use of a compound of formula (I). n . n EFFECT: produced are new heterocyclic compounds, which are useful in hyperproliferative disorder treating. n 29 cl, 3 tbl, 34 ex |
| priorityDate | 2012-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1077.